SpringWorks Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03
SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15SpringWorks shows durable effect for neurofibroma therapy with long-term data
Jun 15SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma
Jun 07We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow
May 31SpringWorks Therapeutics EPS misses by $0.11
May 06SpringWorks Therapeutics announces C-level promotions
Dec 15SpringWorks Therapeutics EPS misses by $0.02
Nov 12CEO
SpringWorks Therapeutics has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Financial Officer | 4.8yrs | US$3.74m | 0.025% $ 789.7k | |
| Chief Operating Officer | 3.3yrs | US$6.64m | 0.26% $ 8.3m | |
| Chief Medical Officer | 2.8yrs | US$4.31m | 0.032% $ 1.0m | |
| Chief Accounting Officer | 4.2yrs | no data | 0.0083% $ 260.3k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Vice President of Communications & Investor Relations | 6.3yrs | no data | no data | |
| General Counsel & Secretary | 4.3yrs | US$2.83m | 0.018% $ 576.0k | |
| Chief People Officer | 3.8yrs | US$2.52m | 0.0065% $ 204.3k | |
| Chief Commercial Officer | 3.2yrs | US$4.94m | 0.014% $ 433.7k |
3.8yrs
Average Tenure
57yo
Average Age
Experienced Management: SWTX's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 4.8yrs | US$520.14k | 0.0080% $ 250.3k | |
| Independent Chairman of the Board | 8.3yrs | US$545.14k | 0.40% $ 12.6m | |
| Independent Director | 6.8yrs | US$508.45k | 0.0080% $ 250.3k | |
| Independent Director | 1.8yrs | US$507.64k | 0.0043% $ 136.1k | |
| Independent Director | 4yrs | US$520.14k | 0% $ 0 |
4.8yrs
Average Tenure
65yo
Average Age
Experienced Board: SWTX's board of directors are considered experienced (4.8 years average tenure).